Operational Report Q2 2020

High level operational report summarising key milestones Q2 2020 and forward looking statement.

Ilya Pharma awarded risk-shared funding by EIT Health

Ilya Pharma awarded Euros 5.3 million from EIC Accelerator to fast track Phase II study of first-in-class ILPI100 advanced therapy for wound treatment in people with diabetes

4000 applicants, 72 SMEs awarded, Ilya Pharmas project among the 1.8 % winners!

Resuming recruitment to the ongoing clinical trial - final cohorts

Operational Report Q1 2020

COVID-19 operations impact

Ilya Pharma’s ILP100 Phase I wound care therapy trial progresses swiftly to multiple dosing

Ilya Pharma, a clinical stage biopharma company, today announced that multiple dosing in the Phase I trial for its lead candidate ILP100 has already commenced. Initial single dosing in three cohorts has been completed in 4 months which represents rapid progress. ILP100 is the first drug based on genetically engineered lactic acid bacteria to be approved to enter trials as a topical treatment. The Company is now preparing for the phase II clinical developments and in response, Ilya has strengthened its clinical development team with two key senior appointments with key experience: ex-Renovo / Smith & Nephew Wound Management David Fairlamb as expert advisor and ex Novartis Andreas Fasth as Head of Clinical Developments.

Ilya Pharma selected to present at the BIO CEO Investor forum in NYC 10-11th of February.

Ilya Pharma will present developments at SwissNordicBio 6th of February 2020 in Zuric

Ilya Pharma will present recent clinical data at Advanced Therapies Congress & Expo 2020 in London March 31